Copaxone News: 51 articles

Teva Announces Copaxone(R) Reaches One Million Patient Years of Experience in the Treatment of Multiple Sclerosis

2010-04-12T10:33:00.000-07:00

(Posted By: Josi Creek)
Approved in 1996, Copaxone(R) is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS)

Ongoing, prospective, clinical trial follow-up reinforces the established efficacy and safety profile of Copaxone(R) in patients treated for more than 19 years

Teva Pharmaceutical Industries, Ltd. /quotes/comstock/15*!teva/quotes/nls/teva (TEVA 63.20, +0.05, +0.08%) announced today that Copaxone(R) (glatiramer acetate injection), has now achieved one million patient years of experience in the treatment of relapsing-remitting multiple sclerosis (RRMS). This analysis is based on internal data submitted annually to the U.S. Food and Drug Administration (FDA).

Click HERE to read the full story.

216 PERSONAL COPAXONE STORIES...with 100's of Tips & Comments from our 2,700 Facebook Friends & 3,300 MySpace Friends

2008-12-26T19:55:00.000-08:00

CLICK HERE TO GO TO THE COPAXONE ARCHIVE OF 216 STORIES & TIPS

2006-11-08T21:32:00.000-08:00

Better patient compliance with Copaxone ollow-up analysis of an ongoing study of multiple sclerosis patients has found that after six years more than half of the patients taking Copaxone had remained on treatment continuously, Teva Neuroscience has said. The study compared these results to patients taking an alternative treatment for MS called interferon beta. Only 30% of patients taking interferon beta remained on the treatment.

The study included patients receiving Copaxone or interferon beta treatments including Avonex, Betaseron or Rebif. All are known as immunomodulatory therapies (IMTs)..

2006-11-08T20:58:00.000-08:00

REBIF & COPAXONE: From new ideas to Nobel prizes, Israeli university research forges ahead
[PHOTO: Professors Aaron Ciechanover, 57, (right) and Avram Hershko, 67, in their lab at the Technion-Israeli Institute in Haifa.]
If the high tech and biotech industries are the engines that have been driving the Israeli economy over the past five years, it is the nation's universities that have provided the fuel: brainpower.

Behind nearly every Israeli business success story is an idea which born in a laboratory in one of the country's impressive institutions of higher learning.

Innovation at Israeli universities, of course, is nothing new. But what has rapidly improved has been the journey from university to the marketplace. Once a rough and rocky path filled with obstacles, the road to commercialization has become smoother and more efficient, thanks to the level of assistance and support provided by the universities themselves.

The past five years has seen a blossoming and expansion of what are known as technology transfer companies: businesses housed on campus that are devoted to taking the products of the university's minds, presenting them to the business world, and guaranteeing, with its proactive role, that the universities benefit financially from the ideas that they foster.

Israel's best-known technology transfer company, admired and imitated around the world, is the Weizmann Institute's Yeda Research and Development.

"In all, Weizmann scientists have been responsible for well over 1,000 registered patents, many of which have been developed commercially.

Among its licenses are two of the four drugs used in the United States and worldwide to treat multiple sclerosis - Copaxone made by Israel-based Teva Pharmaceuticals, whose annual sales top $360 million, and Rebif, made by Ares Serono of Switzerland and developed by its subsidiary Interpharm, whose sales exceed $370 million. "

2006-10-09T08:30:00.000-07:00

Long-Term Data Demonstrated Significantly Better Patient Adherence to COPAXONE(R) versus Interferons in Multiple Sclerosis Treatment. A retrospective follow-up analysis of an ongoing prospective study of relapsing-remitting multiple sclerosis (RRMS) patients (n=285) taking immunomodulatory therapies (IMTs), found that after six years more than half of the patients (41/79) taking COPAXONE(R) (glatiramer acetate injection) had remained on treatment continuously, whereas less than thirty percent of patients (55/206) taking one of the interferon beta (IFN-(beta)) class of drugs remained in the study (pless than 0.0001). The study, which included patients receiving either COPAXONE(R), Avonex(R) (IFN-(beta)-1a IM), Betaseron(R) (IFN-(beta)-1b SC), or Rebif(R) (IFN-(beta)-1a SC), was presented last week at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), in Madrid, Spain.

The results of this follow-up analysis reinforced and extended the four-year results presented at the 15th Meeting of the European Neurological Society (ENS) in 2005, which demonstrated better adherence in COPAXONE(R) patients versus those taking interferon therapies.

"The significantly higher treatment adherence rate demonstrated by COPAXONE(R) patients in this study, coupled with a robust response to treatment, may be meaningful to clinicians when it comes to recommending an initial IMT to patients," said Dr. Judith Haas, Head of the Department of Neurology, Jewish Hospital, Berlin, Germany and lead investigator of this study. "Drop-out rates are an excellent surrogate marker of the long-term efficacy of IMTs, and an important consideration in treating RRMS."...

2006-10-09T07:47:00.000-07:00

2006-10-09T07:43:00.000-07:00

COPAXONE(R) Showed Sustained Benefit on Slowing Brain Tissue Damage in Multiple Sclerosis Patients
Data presented last week at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Madrid, Spain, showed that COPAXONE® (glatiramer acetate injection) may slow the neurodegenerative tissue damage that is a key aspect of multiple sclerosis (MS) disease pathology. Results of the longest, prospective study of annual brain proton MRS imaging in relapsing-remitting multiple sclerosis (RRMS) patients suggested a beneficial effect of COPAXONE® treatment on cerebral axonal injury and recovery.

"These data reinforce the findings of previous studies showing that in addition to reducing relapses in RRMS patients over the long term, COPAXONE® may have the unique ability to slow or prevent neurodegenerative processes by reducing axonal injury and promoting axonal recovery within the central nervous system, and that this benefit is sustained over time," said Omar Khan, M.D., Wayne State University and lead investigator of the study.

In MS, measuring brain n-acetylaspartate (NAA) levels relative to creatine (Cr) (NAA/Cr ratios) via MRS is a method of assessing axonal injury caused by the disease. Decreased levels of brain NAA/Cr ratios are a marker of neuronal damage or degeneration and also correlate strongly to clinical disability; an increase in brain NAA/Cr ratios indicates a recovery of injured nerve cells or neurons in the brain. This study involved annual blinded MRS analyses of NAA/Cr of patients (n=22), over four years.

"Patients in this study who remained on COPAXONE® (glatiramer acetate injection) experienced an increase in mean NAA/Cr, pointing not only to the treatment's effect on slowing accumulation of brain tissue damage as measured by MRS, but to its effect on the recovery of damaged brain tissue," said Khan. "Measuring changes in NAA/Cr ratio throughout the course of the disease is of increasing interest to the MS research community because of data demonstrating its correlation with accumulated disability, pointing to the potential for MRS imaging to serve as a surrogate marker for both disease progression and therapeutic response in clinical practice....."

2006-10-09T07:34:00.000-07:00

New Data Confirmed Antibodies to Copaxone® Do Not Impact Its Established and Sustained Long-Term Efficacy in Multiple Sclerosis

Jerusalem, Israel, September 28, 2006 - New data presented today at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Madrid, Spain, showed that antibodies to COPAXONE® (glatiramer acetate injection) developed in all patients with multiple sclerosis (MS) treated with COPAXONE®, but did not interfere with the efficacy of the drug. Over a mean treatment period of more than six years, patients in this cross-sectional study who were continuously treated with COPAXONE® experienced only a minimal increase in their EDSS score, indicating that the long-term efficacy of the drug was not compromised by treatment-related antibodies.
Studies have shown that neutralizing antibodies (Nabs) develop in 5 percent to 45 percent of all MS patients treated with interferon beta (IFN-β). The presence of Nabs to IFN-β may negatively alter the therapeutic effectiveness of this class of disease modifying drugs which includes IFN-β-1a SC (Rebif®), IFN-β-1b SC (Betaseron®), and IFN-β-1a IM (Avonex®). Patients who test positive for NAbs are more likely to have reduced therapeutic benefits from their interferon beta treatment (measured by the reduction in relapse rate, the reduction in disability progression and the disease activity as evidenced by brain magnetic resonance

"Neutralizing antibodies against IFNs are therefore an important issue for MS management, as their development appear to diminish their clinical efficacy," said Professor Dimitrios Karussis, Department of Neurology, Hadassah University Hospital, Ein-Karem, Jerusalem. "Our data confirms that antibodies to COPAXONE® which develop in all patients do not neutralize the drug's biological activity and do not compromise its established sustained long term effectiveness." he added.
Recent guidelines on Nabs to beta interferons, produced by the European Federation of Neurological Societies (EFNS), recommend that all people with MS being treated with IFN-β be screened after 12 and 24 months of treatment to determine the existence of anti-IFN-β Abs, and that those who have persistently high levels of NAbs after re-testing 3-6 months after the first results, should have their interferon beta treatment discontinued. Furthermore, it is recommended that since NABs are cross-reactive, switch from one IFN preparation to another is of no clinical benefit.

About the Study
Patients in this study (n=126) who had received COPAXONE® (glatiramer acetate injection) from 2 years to 15 years were surveyed to determine levels and types of antibodies to COPAXONE® and to correlate these parameters with treatment outcomes. Serum samples were collected from study participants, and were analyzed for the presence of antibodies to COPAXONE® using ELISA E (enzyme-linked immunosorbent assay) methodology. Clinical data, including the current and previous Expanded Disability Status Scale (EDSS) scores, and the relapse rates, were also collected at the time the serum samples were taken.

Over the mean COPAXONE® treatment period of 6.65 years, sera from only six patients demonstrated minimal in vitro neutralizing activity. In addition, patients were clinically stable for the whole COPAXONE® treatment period, showing a minimal mean increase in EDSS score of 0.65 (mean annual increase = 0.10 per patient). Despite mean disease duration of 10.75 years, the majority of patients (77 percent) surveyed had an EDSS score of less than 4.0, a stage at which they were still fully ambulatory.

In order to further study the subject of NABs to IFNs, Teva Neuroscience, Inc., recently initiated the first-ever study designed to....MORE

2006-10-09T07:31:00.000-07:00

[ECTRIMS]

A new study showed that very active patients who received COPAXONE® (glatiramer acetate injection) therapy alone following short-term induction treatment with mitoxantrone experienced an 89 percent greater reduction (P<0.0001)>

These data were presented today at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Madrid, Spain.

"These new data represent a promising development in the scientific community's effort to identify additional effective treatment strategies for those patients who have particularly aggressive forms of RRMS, many of whom do not respond optimally to traditional disease modifying therapies," said Tim Vollmer, M.D., chairman, Division of Neurology, Barrow Neurological Institute at St. Joseph's Hospital and Medical Center and the primary investigator in this study. "By putting patients on COPAXONE® after a brief induction period with mitoxantrone, we were able to significantly reduce MRI-disease activity in the brain of active RRMS patients and to sustain this benefit throughout the study."

About the Study

This randomized, double-blind study looked at the safety, tolerability and efficacy of COPAXONE® (glatiramer acetate injection) used after short-term induction therapy with mitoxantrone versus COPAXONE® alone. Relapsing-remitting multiple sclerosis (RRMS) patients in this study (n=40) were randomized to receive either COPAXONE® for one year following three months of mitoxantrone (M-GA; n=21), or COPAXONE® alone for 15 months (GA; n=19). The study included patients aged 18-55, who had a Gd-enhancing lesion at the time of an initial screening MRI scan and an EDSS score of ≤6.5. Patients entering the study were considered very active with a mean number of Gd-enhancing lesions of 3.75. Subsequent brain MRIs were performed at screening and months six, nine, 12 and 15.

Results showing a reduction of Gd-enhancing lesions in the M-GA patient cohort compared with the GA cohort were observed as early as six months into the trial (p< p =" 0.0147).">

A relapse was experienced on average eight months prior to baseline in all study participants; after 15 months, the majority of these patients had not experienced a relapse. Patients who received COPAXONE® after mitoxantrone showed a trend in experiencing fewer relapses over the study period. Mean relapse rate during the study period was 0.16 in the M-GA group and 0.32 in the GA group, reflecting a 46 percent greater reduction in relapses in M-GA patients than of those that did not receive mitoxantrone (p=0.31). There was no difference in time to first relapse between the patient cohorts.

Within study participants, the most frequent adverse events (AEs) associated with the M-GA group were infection, nausea and vomiting, menstruation irregularities and alopecia, and were consistent with known effects of mitoxantrone therapy. Injection site erythema was the most common AE in the GA group.

"Mitoxantrone carries certain risks which limit its use to a maximum recommended lifetime dose. These difficulties make mitoxantrone an option that is generally reserved for only a small group of patients who have a poor disease prognosis or whose disease does not respond to first-line treatment," said Tim Vollmer, M.D., chairman, Division of Neurology, Barrow Neurological Institute at St. Joseph's Hospital and Medical Center and the primary investigator in this study. "When used after short-term induction with mitoxantrone, COPAXONE® minimized exposure to mitoxantrone while maintaining treatment effects ongoing, making it a viable treatment option for a broader proportion of the MS population."

Teva has also issued today a press release regarding additional data presented at ECTRIMS on the efficacy and safety of COPAXONE® treatment after short-term combination of COPAXONE® and intravenous steroids, which will be posted at www.tevapharm.com.

2006-10-09T07:29:00.000-07:00

COPAXONE: "Study Showed Treatment with COPAXONE(R) is Associated with Significantly Fewer Days Missed from Work in MS Patients.."Non-Treatment and Treatment with Avonex or Betaseron Had No Significant Impact on Days Missed"..CLICK FOR MORE
"A retrospective analysis of multiple sclerosis (MS) patients comparing patients treated with immunomodulatory agents with untreated patients revealed that only treatment with COPAXONE(R) (glatiramer acetate injection) was associated with significantly fewer days missed from work compared to untreated patients. Neither treatment with Avonex(R) (Interferon beta-1a IM) nor Betaseron(R) (Interferon beta-1b) was associated with significantly fewer days missed from work in comparison to untreated patients. The findings of this study, "Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis," were published in the September issue of the journal WORK.
"Being able to pursue a satisfying work life is an important part of life for most people, yet the symptoms of relapsing-remitting multiple sclerosis (RRMS) and the up and down nature of the disease can make this a challenge for many patients," said MerriKay Oleen-Burkey, PhD, director of Outcomes Research at Teva Neuroscience and a study investigator. "After diagnosis, an estimated 70 to 80 percent of MS patients in the United States leave the workforce. A major goal in the treatment of RRMS is to reduce disease relapses and to provide patients the ability to go on with their lives despite the disease."
Disease relapses in MS can be associated with hospitalization, interference with employment and accumulated disability, leading researchers to suggest that reducing relapse rates may be associated with a reduction in lost work time.

"The results of this study suggest that COPAXONE(R) might be a contributor in helping to keep MS patients participating in the workplace for as long as possible," said Oleen-Burkey. "It is important to consider the results of this study in context given various study limitations, including the retrospective design and a relatively small sample size. It is also important to continue searching for the optimal combination of factors for preserving the working life of MS patients....":

2006-10-09T07:12:00.000-07:00

2006-10-08T21:38:00.000-07:00

2006-08-24T15:33:00.000-07:00

COPAXONE: "Teva Pharmaceuticals ) reported yesterday it hiked the price of its multiple sclerosis drug Copaxone by four percent" - Haaretz - Israel News
:

2006-08-14T22:18:00.000-07:00

2006-08-07T19:29:00.000-07:00

COPAXONE: Teva Initiates Phase III Study to Confirm Increased Efficacy of Higher Dose of Glatiramer Acetate for the Treatment of Relapsing-Remitting MS; Study to Confirm Phase II Results Showing Reduced Relapses and Lesions :
"Teva Pharmaceutical Industries (NASDAQ: TEVA) announced today the initiation of a large Phase III study designed to confirm the positive results from the Phase II study which compared a new higher dose of 40 mg/day dose of glatiramer acetate (GA) to the currently approved COPAXONE(R) (GA) 20 mg/day, whose efficacy and safety have been well established by three pivotal trials and over a decade of experience and clinical research. The study, called FORTE - FORTy mg Efficacy of glatiramer acetate - is beginning the enrollment of approximately 1,000 patients in 160 centers across North America, Europe, Argentina and Israel

The results of the initial nine-month, randomized, double-blind, parallel-group Phase II study were presented at the 58th Annual Meeting of the American Academy of Neurology (AAN) in San Diego, CA, April 1-8, 2006. Patients taking the higher dose of GA had a 38 percent greater reduction in mean cumulative number of gadolinium (Gd)-enhancing lesions as measured by magnetic resonance images (MRI) of the brain compared with those taking the COPAXONE(R) (GA) 20 mg/day dose. In addition, compared to annual relapse rate prior to entry, patients taking GA 40 mg/day experienced a reduced mean on-trial relapse rate of 77 percent whereas patients taking COPAXONE(R) (GA) 20 mg/day experienced a 62 percent reduction. GA 40 mg/day was well-tolerated with a safety profile similar to the currently COPAXONE(R) (GA) 20 mg/day.

"The Phase II study results are very promising and suggest that the established efficacy of COPAXONE(R) can be increased even further with this next generation of GA," said Israel Makov, President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. "The initiation of the FORTE study is part of our commitment to MS patients to develop improved therapies that combine superior efficacy and excellent safety," Makov added.

About the Study

The FORTE study is a 12-month, multinational, multicenter, randomized, parallel-group, double-blind study. Patients will be equally randomized into one of two groups: 40 mg GA once daily or COPAXONE(R) (GA) 20 mg once daily. The study objectives include comparing the efficacy and safety of daily subcutaneous injections of 40 mg/day GA to that of COPAXONE(R) (GA) 20 mg/day in RRMS patients. Confirmed relapses and adverse events will be monitored throughout the study. Patients completing the 12-month phase will continue in the study for an additional 12-month, open-label phase in which all subjects will receive 40 mg/day GA.

Patients and health care providers interested in learning more about the study can visit www.clinicaltrials.gov and enter the trial's identifier code of NCT00337779 for more information......"

2006-08-02T10:15:00.000-07:00

Teva Announces Global In-Market Second Quarter Sales of Copaxone(R) Increased 22% to $353 Million"

2006-06-21T16:09:00.000-07:00

"What ails Teva?"...more:
"...The second factor is related to Teva's ethical multiple sclerosis drug, Copaxone, which breaks new sales records every quarter. Many analysts believe that Teva's ability to increase Copaxone sales has peaked because of the US Food and Drug Administration (FDA) marketing approval, albeit restrictive, for Tysabri, made by Biogen Idec Inc....."

2006-06-21T07:28:00.000-07:00

Copaxone/Glatiramer Acetate Injections Reduced Relapses by 75% in Both Treatment-Naive Multiple Sclerosis Patients and Those Failing Interferon Beta-1b
DocGuide
"More than 80% of All Patients Experienced an Improved or Stable Kurtzke Expanded Disability Status Scale (EDSS) Score

KANSAS CITY, MO -- June 20, 2006 -- Both relapsing-remitting multiple sclerosis (RRMS) patients switching from Betaseron® (interferon beta-1b) to Copaxone (glatiramer acetate injection) and treatment-naïve RRMS patients achieved reductions in relapse rate compared to those experienced in the two years prior to study entry, according to a recent study published in Acta Neurologica Scandinavica.

In this study, Copaxone was shown to reduce annual relapse rate by 75% in both patients switching from Betaseron® and in patients who were treatment-naïve; a high proportion of patients remained relapse free (treatment-naïve, 69.5%; prior interferon beta-1b, 68.4%) for the entire trial duration of 3.5 years. In addition, the majority of patients (>80% in both cohorts) demonstrated an improved or stable Kurtzke Expanded Disability Status Scale (EDSS) score (a measure of neurological disability) over the course of Copaxone treatment.

"The importance of using immunomodulatory treatment to manage disease activity and disability in RRMS is already established," said Howard Zwibel, MD, Medical Director of Baptist Health Doctors Hospital Multiple Sclerosis Center and the primary investigator of this study. "In this study, treatment with Copaxone showed clinical benefit, both to patients who had failed treatment with Betaseron® and as a first-line option for patients who were new to treatment with disease modifying drugs."

About the Study
In this 3.5 year, prospective, open-label study, a total of 805 RRMS patients were divided into two patient cohorts. One cohort consisted of patients who had previously taken Betaseron® (prior IFNB-1b cohort, n=247), had discontinued due to lack of efficacy or tolerability and were switched to Copaxone (glatiramer acetate injection), and the other cohort included patients who were treatment-naïve upon entering the study (treatment-naïve cohort, n=558) and initiated therapy with Copaxone.

Baseline characteristics differed between the two patient cohorts; patients in the prior INFB-1b cohort were older, showed signs of more advanced disease and had higher baseline EDSS scores than patients in the treatment-naïve cohort. Mean Copaxone (glatiramer acetate injection) treatment duration was 14.8 (prior INFB-1b cohort) and 20.3 months (treatment-naïve cohort).

Compared with the two years prior to study entry, annual relapse rates decreased by 75% in both the prior INFB-1b cohort (0.42±0.84) and the treatment-naïve cohort (0.34±0.71), (P =.1482). A high population of patients in the trial remained entirely relapse free; 68.4% of prior IFNB-1b patients (n=169) and 69.5% of treatment-naïve patients (n=388), (P =.9). For patients who remained relapse free, the mean duration of Copaxone treatment was 453 and 565 days in the prior IFNB-1b and treatment-naïve cohorts, respectively.

Data from the last available neurological assessments of patients in this trial indicated that more than 80% of patients in the prior INFB-1b and treatment-naïve cohorts had "stable or improved" EDSS scores compared with EDSS scores at study entry (defined as an increase of less than 1.5 points overall). Fewer than 10% of patients in either cohort experienced protocol-defined sustained progression of disability; thus, patients in the prior IFNB-1b cohort received significant therapeutic benefit from Copaxone despite more advanced disease and less mean treatment duration with Copaxone. Furthermore, regardless of entry EDSS scores, at both 12 and 18 months into the trial and at last observation, mean changes in EDSS were less than 0.5 steps in both cohorts.

"Copaxone (glatiramer acetate injection) was effective, well-tolerated and safe in this study," said Dr. Zwibel. "The efficacy results shown here are similar to the results of another recent treatment-switch study published in June 2006 in the European Journal of Neurology, where data showed that patients who switched from Avonex® (interferon beta-1a) to Copaxone experienced a significant decrease in relapse rate as well as sustained or improved EDSS scores.........."
"

2006-05-31T09:06:00.000-07:00

COPAXONE - AVONEX...Teva Neuroscience, Inc. (TEVA) News Release: COPAXONE Reduced Relapses And Stabilized Disability As Measured By Expanded Disability Status Scale, When Avonex Failed :

"Relapsing-remitting multiple sclerosis (RRMS) patients failing Avonex(R) (interferon beta-1a) therapy as defined in the study, achieved significant reductions in relapse rates and in Expanded Disability Status Scale (EDSS) scores, a measure of disability, upon switching to COPAXONE (glatiramer acetate injection). In a study published in the June issue of the European Journal of Neurology, COPAXONE was shown to reduce annual relapse rate by an additional 57 percent over Avonex, and that neurologic disability, as measured by the EDSS, did not worsen in 86 percent of patients.
'Our data demonstrated the benefits of COPAXONE in reducing relapse rate in patients who were not effectively treated or could not tolerate other immune modulating therapies,' reported Dr. Omar Khan, M.D., associate professor of neurology and director of experimental therapeutics/clinical research, Multiple Sclerosis Center, Wayne State University, and senior author of the study.
A series of 85 consecutive RRMS patients treated with Avonex(R) for at least 18 months who experienced suboptimal clinical efficacy (at least one relapse in the previous year, n=62) or persistent intolerable toxicity (elevated liver function tests, low white blood cell counts, or post-injection fever, weakness, or fatigue for more than 24 hours after every injection, n=23), were switched to COPAXONE in this open-label study and followed prospectively for an additional 36 to 42 months (average 37.5 months). While on COPAXONE( therapy, patients were seen every six months for neurological examinations, including EDSS scores.
Annualized relapse rate for the entire patient group after switching to COPAXONE(R) (glatiramer acetate injection) was reduced by 57 percent from 1.23 on Avonex(R) to 0.53 (p=0.0001). In the subset of patients who switched to COPAXONE because of insufficient efficacy on Avonex (n=62), the reduction was even more significant (61 percent), from 1.32 to 0.52 (p=0.0001). Patients who switched to COPAXONE because of persistent toxicity on Avonex(R) (n=23), experienced an additional 23 percent reduction which did not reach statistical significance.
In all patients, the average EDSS scores, as a measure of neurological disability, significantly improved during the more than three years of COPAXONE(R) therapy, decreasing from 3.50 to 3.08 (p=0.0001). Improved or stable EDSS scores occurred in 86 percent of patients.
'We recognize the limitations of our study, such as the open-label design and lack of prospective follow-up in patients while receiving IFN beta-1a,' stated Dr. Khan. 'However, our results corroborated another larger prospective open-label study by Howard Zwibel, M.D., Medical Director of Health South Doctors' Hospital Multiple Sclerosis Center, which demonstrated reductions in relapse rates in patients switched from Betaseron to COPAXONE, and suggested that clinical observations including relapse rates, patient tolerability, and toxicities assessed by serum laboratory parameters are valuable criteria for determining when a switch in therapy is warranted.,,,,'"

Team COPAXONE and Sutton Motorsports: Kelly Sutton returns with high hopes

2006-02-08T21:25:00.000-08:00

READ MORE"Her hope is to better the 17th place finish in the 2005 Daytona 250 and to improve her final standings of 29th last year. The lady racer who battles MS every day holds the honor of being the top-earning female in the history of the Truck series...."

Copaxone may offer protection from axonal injury

2006-01-24T09:13:00.000-08:00

More: "Clinical research data, published in the journal Multiple Sclerosis, provided evidence that Copaxone ( Glatiramer ) may offer protection from axonal injury and induced neuronal metabolic recovery in patients with relapsing remitting multiple sclerosis ( RRMS ).

In a pilot study of 18 RRMS patients using brain imaging techniques, Copaxone was found to produce significant increases in n-acetylaspartate/creatine ( NAA/Cr ) ratio, an indicator of neuron and axon integrity, compared to four untreated control patients after one year of treatment............"

6 Helpful Injection Tips

2006-01-11T11:46:00.000-08:00

Copaxone (Glatiramer Acetate) Demonstrated Protection Against Neuronal Injury In Relapsing-Remitting MS

2005-12-13T20:48:00.000-08:00

Clinical research data published in the December issue of Multiple Sclerosis provided evidence that Copaxone® (glatiramer acetate injection) may offer protection from axonal injury and induced neuronal metabolic recovery in patients with relapsing-remitting multiple sclerosis (RRMS). MORE

Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action

2005-11-04T00:41:00.000-08:00

MORE....Entrez PubMed

The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients

2005-11-04T00:39:00.000-08:00

CONCLUSION: GA can be considered as a good treatment alternative to IFN-beta-intolerant MS patients. However, some patients were not able to use available immunomodulative treatments, which emphasizes the need for new therapeutic options. The lack of MxA protein induction confirms the different mechanisms of action of GA and IFN-bMORE....Entrez PubMed

Twenty-four-month comparison of immunomodulatory treatments – a retrospective open label study in 308 RRMS patients treated with beta interferons or g

2005-11-04T00:37:00.000-08:00

Twenty-four-month comparison of immunomodulatory treatments – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate CopaxoneBlackwell Synergy: Eur J Neurol, Vol 12, Issue 11, pp. 916-917: Hass J, Firzlaff M (2005). (Abstract)

COPAXONE STUDY: CCL2 and CCL5 levels in the peripheral blood of multiple sclerosis patients treated with Glatiramer Acetate (Copaxone).

2005-11-03T06:20:00.000-08:00

MORE...Entrez PubMed

Pre-Filled Syringe For Copaxone Users Makes Injection Process Easier

2005-10-30T08:34:00.000-08:00

" "With Copaxone® PFS there is no mixing, no preparation and fewer supplies are needed, ensuring increased accuracy, better compliance, and less chance for error or contamination. Copaxone® PFS is a consistent, convenient, and complete way for patients with MS to manage their therapy," explains Dr. Jean Godin, Medical Director, Teva Neuroscience, maker of Copaxone®. "Copaxone* PFS provides the same efficacy as the old format, in a more convenient and easier-to-use injection format. It makes it easier for patients with MS to focus more on their lives and less on their therapy." For neurologists, nurses and pharmacists, compliance and adherence to treatment are among the most important factors in any therapy. Patients frequently cited the fact that the PFS saves time and is easier to administer than the previous mixable formulation. "I'm very excited about the pre-filled syringe because it will make it easier for me to maintain my therapy without feeling like MS is controlling me. This will definitely improve my overall quality of life," comments Dave Chisamore, who has had MS since 1999 and been taking Copaxone® since June 2000. "
MORE: docguide.com

COPAXONE: Only MS Therapy Available Without Warnings or Precautions for Liver Damage

2005-10-30T08:30:00.000-08:00

"Given the recent news surrounding the multiple sclerosis (MS) therapies, Teva Neuroscience announced today that COPAXONE(R) (glatiramer acetate injection) is the only available relapsing-remitting MS (RRMS) therapy that does not carry a warning or precaution for liver damage and does not require additional laboratory testing. This clarification is important due to recent announcements regarding two approved products in the MS market. The recent marketing suspension on one newly approved product and the FDA-issued warning for liver damage on the other prompted Teva Neuroscience to clarify the attributes of COPAXONE(R).

The multiple sclerosis community is asking tough questions about MS therapies. Teva Neuroscience, a leader in the field of neurology, understands the concern and confusion weighing on the minds of people living with MS and their carepartners. The company wants to reassure both physicians and patients that there is a wealth of data to support the efficacy and safety of their product, COPAXONE(R).

The science behind COPAXONE(R) has been developed over many years, including an ongoing, long-term, prospective extension trial that has spanned the last 12 years. The importance of researching and weighing the evidence when selecting a therapy is critical. COPAXONE(R) is an RRMS therapy supported by three Class I Phase III trials (prospective, randomized, and controlled) establishing efficacy and safety(1,2,3). "Class I" means the studies met the highest standards for quality according to experts(4).

The three studies included two two-year studies, showing how effective COPAXONE(R) (glatiramer acetate injection) is in reducing relapses over the long term(1,2). One of the two-year studies was extended as an open-label trial to 12 years with a commitment to extend to 15 years -- making it the longest continuous study ever of patients with RRMS(5). A third study showed people on COPAXONE(R) had steady reductions in the number of new brain MRI lesions(3). Furthermore, COPAXONE(R) is presumed to have a dual mechanism of action both outside and within the central nervous system (where MS is active) to reduce inflammation at the site of brain lesions(6,7).

Following stringent regulatory review, COPAXONE(R) has received approval for treatment of RRMS in 42 countries worldwide. These approvals were based on well-controlled Phase III trials demonstrating efficacy, safety, and tolerability.

Additionally, numerous other open-label studies have supported the effectiveness of COPAXONE(R)(8-12). Clinical experience with COPAXONE(R) has led to endorsement of its use in published guidelines by the American Academy of Neurology, the National Multiple Sclerosis Society, and the Association of British Neurologists.

"We want people living with MS to feel confident in their therapy decision and take comfort in the fact that COPAXONE(R) has been studied for more than a decade and does not carry a precaution or warning for liver damage," said Larry Downey, Teva Neuroscience President and Chief Executive Officer. "In addition to clinical data, COPAXONE(R) has more than 340,000 patient-years of exposure in post-marketing data through November 2004."

As part of its commitment to the MS community, Teva Neuroscience created Shared Solutions(R), a free service offering support, knowledge, and answers for anyone affected by MS. People living with or touched by MS are encouraged to call Shared Solutions(R) at (800) 887-8100 for answers to questions about living with the disease and drug therapy."MORE: medicalnewstoday.com

2 VIDEOS: "Hi! I'm Joyce Moore...I'm on Copaxone & I have some tips for you"

2005-10-23T18:08:00.000-07:00

Please watch my 2 videos on the left column of this page!

"A helpful tip for newly diagnosed MS patients.
"Important advice on choosing MS medication "

What is MS University?

2005-10-23T15:48:00.000-07:00

Looking for an opportunity to enhance your MS knowledge online?
Well, then MS University® is what you need. MS University® gives you access to a vast range of MS information, resources, and knowledge presented throughout a wide range of course offerings. It's like attending college, but from the comfort of your home. There's even a library, bookstore and student union center. And this valuable education is free.

We invite you to visit the MS University® campus today. You'll find that MS University® is more than just a Web site, it's a unique learning experience.

Educational Topics to Help Develop Your Understanding of MS
Virtually every topic on MS is covered, including discussions about therapy options, research and information to help you better manage MS.

Choose From an Extensive Course List
Just like a real university, you can choose from an extensive list of courses. Learn about the history of MS, how it's diagnosed, the natural course of the disease, patient advocacy and much more. It's easy. Just go to "Classes" on the side bar and click. You can even print the chapters to read the materials offline.

Advance to New Class Levels as Your Knowledge Grows
At MS University®, you have the opportunity to attend a virtual "freshman to senior" program. A Continuing Education section recently was added as an enhancement to our four-year program. Just like attending college, each level builds upon the knowledge of the previous courses. Here's what's covered:
MORE

Newly Diagnosed

2005-10-23T15:42:00.000-07:00

MORE: "MS is one of the most prevalent diseases affecting the central nervous system (CNS). In order to help you make an informed decision regarding the right therapy for you and to help you learn about the disease, the marketers of COPAXONE have created this section for you.

MS is a chronic disease of the CNS affecting approximately 300,000-500,000 people in the U.S. The exact cause of MS is unknown. It’s believed that an autoimmune process, which may be triggered by a virus and/or environmental factors, destroys the myelin sheath of nerve fibers. Multiple sclerosis is generally diagnosed in individuals between the ages of 20 and 40. Women develop MS at a rate of 2-3 times that of men."

Newly DiagnosedV

2005-10-23T15:33:00.000-07:00

MS is one of the most prevalent diseases affecting the central nervous system (CNS). In order to help you make an informed decision regarding the right therapy for you and to help you learn about the disease, the marketers of COPAXONE® have created this section for you.

MS is a chronic disease of the CNS affecting approximately 300,000-500,000 people in the U.S. The exact cause of MS is unknown. It’s believed that an autoimmune process, which may be triggered by a virus and/or environmental factors, destroys the myelin sheath of nerve fibers. Multiple sclerosis is generally diagnosed in individuals between the ages of 20 and 40. Women develop MS at a rate of 2-3 times that of men. For more information about MS visit MS University® or MSWatch®.

Importance of Therapy
Being a chronic disease, MS cannot be cured. Research continues to show that early treatment of MS is critical in reducing the frequency of exacerbations.
The effects of exacerbations can be cumulative over time, if not prevented.
MORE/a>

Team COPAXONE

2005-10-23T15:27:00.000-07:00

Team COPAXONE® celebrates the accomplishments of people who have refused to let MS stand in the way of their dreams. Like any team, this is a group of individuals with different talents, and different lives, yet one common goal: to live the life they've imagined.MORE

Clay Walker: his multi-city, nationwide patient program series called Sharing Solutions for MS

2005-10-23T15:22:00.000-07:00

With the success of 11 programs under his big belt buckle going into the fall, country music star Clay Walker has decided to add three more cities to his multi-city, nationwide patient program series called Sharing Solutions for MS.

Walker will share his journey with multiple sclerosis (MS) and drug therapy with others living with MS and their carepartners in Kansas City, Billings, and New York City in October and November 2005.

“These programs are about uplifting people. It’s about encouraging them, it’s about sharing the faith I have that there’s a drug therapy out there for everyone. I truly believe one day we will find a cure for this disease, but until then, we have to do everything we can to fight it,” said Walker. “If I can convince one person at every program to go out there and take that first step, it’s been worth i
MORE

Starting COPAXONE

2005-10-23T15:14:00.000-07:00

There’s growing agreement about the role therapy plays in managing MS. In 1998, the Medical Advisory Board of the National Multiple Sclerosis Society (NMSS) made its first formal statement (Disease Management Consensus Statement) advocating the use of MS therapy. The NMSS advises starting MS therapy as early as possible and continuing with treatment indefinitely. Support for this statement comes from all the available data that show MS is at work even in the absence of clinical symptoms.
MORE

Take Charge with COPAXONE

2005-10-23T15:11:00.000-07:00

If you’re currently considering your MS treatment options, it’s important to understand that starting therapy as soon as possible can make a positive difference in the course of your MS.

New beginnings can be overwhelming, but your therapy can become a proactive way of helping to take control and committing to your future. One way to take charge of your life is by starting and staying on an approved therapy like COPAXONE®.
MORE

Welcome to Copaxone.com

2005-10-23T15:07:00.001-07:00

MOREThe official site for Copaxone offering information on Copaxone and multiple sclerosis. Read up on the latest MS News, locate MS programs in your area....

Copaxone Safe For Pediatric Multiple Sclerosis: Presented at ECTRIMS

2005-10-21T15:33:00.000-07:00

THESSALONIKI, GREECE -- October 3, 2005 -- Glatiramer acetate (Copaxone) treatment of children with multiple sclerosis is safe, with a safety profile similar to that found among adults, researchers reported here on September 29th at the 21st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

"Children get multiple sclerosis, and we found in this study children can be treated with multiple sclerosis in the same way adults can be treated," said lead investigator Lauren Krupp, MD, professor of neurology and director, National Pediatric Multiple Sclerosis Center, State University of New York Medical Center, Stony Brook, New York, United States. "We found that they can be treated equally safely with Copaxone, or glatiramer acetate."

The investigators conducted a retrospective chart review of 16 girls and 11 boys with a mean age of 12.2 years at onset of relapsing remitting multiple sclerosis (RRMS) who were diagnosed at or before age 18 years. They included subjects from 5 North American sites.

Subjects received off-label treatment with glatiramer acetate 20 mg/day, injected subcutaneously daily for a mean of 20.0 months (range, 2.0-60.0 months). Patients started glatiramer acetate treatment at mean age of 14.1 years and at a mean of 13.2 months postdiagnosis.

Sixty-four adverse events were reported among 17 patients. Less than 6% of reported adverse events resulted in temporary or permanent discontinuation of therapy after a mean of 14.8 months on glatiramer acetate.

Most frequently reported adverse events were comparable to the adult data, and they included injection site reactions in 8 patients (23.4%), skin reactions in 2 patients (12.5%), bronchitis in 4 patients (6.3%), and dyspnea in 3 patients (4.7%).

There was no evidence of abnormal laboratory values or vital signs.

"In summary," the authors wrote in their abstract, "[glatiramer acetate] was extremely well tolerated."

The researchers calculated the annual relapse rate for the patients who had at least 12 and 24 months of pre- and posttreatment data. They observed a 56% decrease in the frequency of relapse in the first 12 months and a 58% decrease in relapse frequency was seen for the smaller subset in the patients for whom 24-months posttreatment data was available.

Dr. Krupp concluded, "This medication, which is safe in adults, is equally safe in children. The clinical implication is that it's safe, so use it."

[Presentation title: Safety and Tolerability of Copaxone(R) in Paediatric Patients With Relapsing-Remitting Multiple Sclerosis. Poster 332]

Long-term Use Copaxone for MS Appears Safe and Efficacious: Presented at ECTRIMS

2005-10-06T16:13:00.000-07:00

Patients with relapsing-remitting multiple sclerosis who used glatiramer acetate (Copaxone) for up to 26 years show sustained efficacy and safety of treatment, researchers reported here. "These were patients in the 'compassionate use' program for this drug before any multiple sclerosis drugs were approved," said investigator Rivka Riven Kreitman, MD, Vice-president for Research and Development, Teva Pharmaceutical Industries Netanya, Israel...."These patients have been very stable on Copaxone [GA] for the long term, and have had very few relapses," he explained. "We saw very few safety issues and very good efficacy." MORE

Twenty-Six Year Data With COPAXONE(R) Reinforce Clinical Efficacy and Safety in Relapsing-Remitting Multiple Sclerosis

2005-10-03T15:41:00.000-07:00

Study Represents Extensive, Continuous Clinical Experience With Immune Modulating Therapy

Clinical experience and study data with COPAXONE® (glatiramer acetate injection) in relapsing-remitting multiple sclerosis (RRMS) patients with active disease (mean annual relapse rate of 2.9) now span more than a quarter of a century. In a long-term, open-label, compassionate use study of up to 26 years (prior to any immune modulating therapies approved by the Food and Drug Administration (FDA)), presented at the 21st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), clinical efficacy and safety data demonstrated reductions in relapse rates, slowed disease progression, and continued tolerability of COPAXONE.

"To see the long-term positive impact on disease progression in these patients on COPAXONE® is very helpful for clinicians and patients making treatment decisions, especially since long-term data with other therapies are scarce," said Dr. Aaron Miller, professor of neurology, Department of Neurology, Mount Sinai School of Medicine, New York, and lead investigator on the study. "Long-term data reinforcing the clinical utility, such as this experience with COPAXONE®, can be reassuring for patients and physicians when making treatment choices."

The author reported the long-term clinical experience in 46 RRMS patients treated with COPAXONE® for 1-26 years (average 10.5 years). Assessment of clinical effectiveness included annual relapse rates and Extended Disability Status Scale (EDSS) scores.

Safety was determined by reports of adverse effects. Patients were seen every six months. Of the original 46 patients, 18 remain active in the study, and of the 28 who withdrew, patient decision to withdraw was the most common reason (54 percent).

At entry, based on a patient's entire history, mean annual relapse rate was 2.9+/-1.4 (range: 1-7). At last clinical observation, mean annual relapse rate for 24 of 42 patients on COPAXONE® (glatiramer acetate injection) was reduced (0.1+/-0.2, p < 0.0001). In terms of EDSS, 24 of 42 (57%) patients had improved or unchanged EDSS scores at last observation compared to pretreatment entry of 3.0+/-1.8 (range: 0-6.5). Over the long course of the study, a non-significant change in average EDSS score was observed (3.0+/-1.8 at entry vs. 3.8+/-2.5 at last observation). Only 8 of 34 (23.5 %) patients with entry EDSS scores less than six, progressed to an EDSS score of six or more with average disease duration of greater than 17 years. For those patients remaining in the study (at the time of data cut-off for this abstract, n=18) with average disease duration greater than 24 years, only 26.7 percent progressed to EDSS greater than or equal to six. This compares favorably to a natural history cohort, which shows 50 percent progressing to six or greater at 15 years after disease onset. Long-term COPAXONE® therapy was well tolerated, and patients reported adverse events similar to those experienced in short-term trials.

About COPAXONE®

Current data suggest COPAXONE® is a selective MHC class II modulator. COPAXONE® is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis. The most common side effects of COPAXONE® are redness, pain, swelling, itching, or a lump at the site of injection, weakness, infection, pain, nausea, joint pain, anxiety, and muscle stiffness.

COPAXONE® (glatiramer acetate injection) is now approved in 44 countries worldwide, including the United States, Canada, Mexico, Australia, Israel, and all European countries. In Europe, COPAXONE® is marketed by Teva Pharmaceutical Industries Ltd. and sanofi-aventis. In North America, COPAXONE® is marketed by Teva Neuroscience.

Teva Pharmaceutical Industries Ltd. (NasdaqNM:TEVA - News), headquartered in Israel, is among the top 20 pharmaceutical companies in the world. Close to 90 percent of Teva's sales are in North America and Europe. The company develops, manufactures, and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system.

Teva Pharmaceuticals USA and Teva Neuroscience, Inc. are subsidiaries of Teva Pharmaceutical Industries Ltd. Teva Neuroscience, Inc. markets COPAXONE®. COPAXONE® is a registered trademark of Teva Pharmaceutical Industries Ltd.

See additional important information at http://www.copaxone.com/pi/index.html or call 1-800-887-8100 for electronic releases. For hardcopy releases, please see enclosed full prescribing information.click

Copaxone spray clears Alzheimer's brain plaques

2005-08-16T16:50:00.000-07:00

Click to read... A new nasal vaccine for Alzheimer’s disease has cleared plaques from the brains of affected mice and will be tested in humans in 2006.They decided on a combination of glatiramer acetate (Copaxone), an approved MS drug that acts as a decoy for errant immune-system attacks, and Protollin, an adjuvant that stimulates innate immunity.

It was given as a nasal mist, a technique Weiner’s lab has had a long interest in. “And it worked,” says Weiner. The combination reduced amyloid beta in the mouse brains by 83% compared to controls.

“The results were quite striking,” says Joanne McLaurin at the University of Toronto, Canada, who has worked extensively on Alzheimer’s vaccines. The idea that inflammation might be helpful in clearing amyloid plaques was first raised a few years ago by a different team, she notes: “The idea is very interesting.”

As always, the question is whether what works in an animal model will work in humans. “Anytime you move from mouse to man there are risks,” says Weiner.

Patient Information and/or Financial Assistance

2005-08-07T13:54:00.001-07:00

Shared Solutions 800-887-8100

www.copaxone.com www.sharedsolutions.com www.mswatch.com www.msdialogue.com

Patient Information and/or Financial Assistance

2005-08-07T13:54:00.000-07:00

Shared Solutions 800-887-8100

www.copaxone.com www.sharedsolutions.com www.mswatch.com www.msdialogue.com

MS Neighborhood : Copaxone

2005-08-03T22:44:00.000-07:00

LINKCopaxone (glatiramer acetate for injection) has demonstrated benefit in effectively reducing the number of relapses in people with relapsing-remitting multiple sclerosis.

Avonex and Betaseron are interferons, which affect many immune reactions in the body.

Copaxone is thought to modify those elements within the immune process that are believed to be responsible for MS.

While it's not known exactly how Copaxone works, it's believed to block myelin-damaging T-cells in the body by serving as a myelin decoy.

This is believed to stimulate suppressor T-cells and inhibit effector T-cell growth and interleuken-2 and gamma interferon secretion.

Copaxone is the first nonsteroidal, non-interferon MS drug therapy available to people living with relapsing-remitting multiple sclerosis.

The most commonly observed adverse reactions associated with the use of Copaxone are injection site reactions (redness, pain, inflammation, itching, a lump at the site of injection), flushing, chest pain, weakness, infection, pain, nausea, joint pain, anxiety and muscle stiffness.

Some patients have reported an immediate post-injection reaction characterized by flushing or chest tightness with heart palpitations, anxiety and difficulty breathing immediately after using Copaxone.

In clinical trials, these symptoms occurred rarely, generally appeared within minutes of the injection, lasted approximately 15 minutes and resolved without further problem

2005-07-31T00:03:00.000-07:00

CLICK HERE

2005-07-30T23:59:00.000-07:00

"What is COPAXONE?"

2005-07-30T23:48:00.000-07:00

CLICK HERE: COPAXONE® (glatiramer acetate injection) is a unique, effective, and well-tolerated therapy that effectively reduces new brain lesions and the frequency of relapses in people with relapsing-remitting multiple sclerosis.

COPAXONE® can help limit the impact of multiple sclerosis on your daily life by reducing relapses. Two clinical trials showed that COPAXONE® reduced relapse rates by 29% (1.19 vs. 1.68 for placebo, p=0.055) and 75% (0.6 vs. 2.4 for placebo, p=0.005) in a two-year period.

In addition to reducing relapses, COPAXONE® has also been proven to reduce new, gadolinium-enhancing brain lesions

Copaxone (Glatiramer Acetate Injection) May Protect Against Axonal Injury Over the Long-Term in Relapsing-Remitting Multiple Sclerosis

2005-07-28T01:29:00.000-07:00

--CLICK FOR LINK TO COMPLETE ARTICLENew data presented at the European Neurological Society Meeting (ENS) demonstrated key clinical and magnetic resonance imaging (MRI) effects of Copaxone(R) (glatiramer acetate injection) in the treatment of relapsing-remitting multiple sclerosis (RRMS).

Results highlighted sustained beneficial effects on cerebral axonal injury and the value of starting Copaxone treatment early to slow the accumulation of long-term disability as measured by the Expanded Disability Status Scale (EDSS).

MRS results suggest beneficial effect of Copaxone on cerebral axonal injury

COPAXONE® SHOWED GREATEST REDUCTION IN LONG-TERM RELAPSE RATE AMONG MS TREATMENTS

2005-07-26T22:41:00.001-07:00

LINKFour-year follow-up data showed COPAXONE® superiority; extends recently published two-year results

Teva Neuroscience

2005-07-26T22:39:00.000-07:00

LINKTeva Neuroscience is the maker of Copaxone (Glatiramer Acetate for Injection), approved for the treatment of relapsing-remitting multiple sclerosis. Teva is also the sponsor of MS Watch, the first fully integrated, interactive disease management Web application for person with multiple sclerosis. MS Watch is available free of charge to all MS patients and their health care providers.

Welcome to SharedSolutions.com

2005-07-26T21:58:00.000-07:00

LINK TO COPAXONE HELP SITE

Participate in a Live Audio Web Chat: Hear Clay Walker's Message of Hope and Empowerment

2005-07-26T21:53:00.000-07:00

link

Wholesale prices for Avonex jumped in May by 8 percent, and Copaxone rose 9.4 percent when Tysabri was pulled from the market

2005-06-06T18:47:00.000-07:00

LINK

2005-03-05T19:22:00.000-08:00

MULTIPLE STUDIES DEMONSTRATE CONFIDENCE IN THE EFFICACY AND SAFETY OF COPAXONE

CLICK TO READ